Choosing RTSM? Evaluate The Team Running It, Not Just The Software

By Chuck Harris, founder and COO, Korio

When evaluating RTSM (Randomization and Trial Supply Management) solutions, the conversation often gravitates toward feature lists and line-item costs. While software capabilities are the foundation, the true success of a clinical trial often hinges on the expertise of the team steering the platform. A robust system can still falter if the project managers lack the clinical depth to anticipate regulatory hurdles or the technical fluency to guide study design decisions. A lack of strategic guidance often leads to brittle, custom-built logic that becomes a liability during protocol amendments or regulatory audits. True value in an RTSM partner lies in continuity and clinical fluency; having a dedicated team that stays from kickoff to closeout ensures that when the study inevitably changes, the response is agile rather than disruptive. Choosing an RTSM partner is as much about selecting the right people as it is about the technology.